Death knell sounds for CB1 antagonists
This article was originally published in Scrip
Anti-obesity drugs that target the cannabinoid 1 receptor look set to be consigned to drug development history after the discontinuation of the two most advanced of these products in this class. Sanofi-Aventis is stopping all clinical trials of Acomplia (rimonabant) following its recent suspension in the EU because of psychiatric safety concerns, and Pfizeris discontinuing its Phase III candidate CP-945,598.
You may also be interested in...
Over 50 cannabinoid drugs are in development, most commonly targeting central nervous system diseases. Analysts think the relaxation of restrictions on medical cannabis is helping with perception problems, but so far there’s little evidence the market isn’t just smoke and mirrors.
This quarter has already seen a complete response letter for Iterum Therapeutics’ antibiotic sulopenem but a raft of other products are expecting approval decisions from the US Food and Drug Administration in the next three months. With the help of analysts at Biomedtracker, Scrip takes a look at 10 of the more interesting ones.
Sanofi is beefing up its investment in mRNA vaccine technology with a €400m annual injection into a dedicated mRNA Center of Excellence as it seeks to be at the forefront of the next generation of candidates.